VTYX
Ventyx Biosciences, Inc.
Key Financials
Net Income
$-135122000
↑ 30.0%
Operating Income
$-148450000
↑ 28.6%
EPS (Diluted)
$-1.97
↑ 40.3%
Total Liabilities
$22.5M
↓ 33.3%
Shareholders' Equity
$254.0M
↑ 4.1%
Cash & Equivalents
$27.3M
↓ 47.1%
Total Assets
$276.6M
↓ 0.4%
Operating Cash Flow
$-130873000.00
↑ 21.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/14/2026 | View on SEC |
| SCHEDULE 13G/A | 5/14/2026 | View on SEC |
| 15-12G | 3/16/2026 | View on SEC |
| EFFECT | 3/6/2026 | View on SEC |
| EFFECT | 3/6/2026 | View on SEC |
| SCHEDULE 13D/A | 3/5/2026 | View on SEC |
| 4 | 3/4/2026 | View on SEC |
| 4 | 3/4/2026 | View on SEC |
| 4 | 3/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VTYX |
| Company Name | Ventyx Biosciences, Inc. |
| CIK | 1851194 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 7604076511 |